Kuo-yen Huang
TPQ, Taiwan
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 33 publications
The ACE2 decoy receptor can overcome immune escape by rapid mutating SARS-CoV-2 variants and reduce cytokine induction and clot formation.
Journal: Journal of biomedical science
Published: March 04, 2025
The role of PM2.5 exposure in lung cancer: mechanisms, genetic factors, and clinical implications.
Journal: EMBO molecular medicine
Published: September 07, 2024
Development of nanoparticles incorporated with quercetin and ACE2-membrane as a novel therapy for COVID-19.
Journal: Journal of nanobiotechnology
Published: October 15, 2023
Diarylheptanoid 35d overcomes EGFR TKI resistance by inducing hsp70-mediated lysosomal degradation of EGFR in EGFR-mutant lung adenocarcinoma.
Journal: The Journal of biological chemistry
Published: October 20, 2022
PM2.5 promotes lung cancer progression through activation of the AhR-TMPRSS2-IL18 pathway.
Journal: EMBO molecular medicine
Published: October 10, 2022
Using host receptor as a decoy to treat COVID-19: a solution for immune escape?
Journal: EMBO molecular medicine
Published: September 12, 2022
A siRNA targets and inhibits a broad range of SARS-CoV-2 infections including Delta variant.
Journal: EMBO molecular medicine
Published: October 18, 2021
Psorachromene induces apoptosis and suppresses tumor growth in NSCLC cells harboring EGFR L858R/T790M/C797S.
Journal: Phytotherapy research : PTR
Published: September 03, 2021
Growth Suppression in Lung Cancer Cells Harboring EGFR-C797S Mutation by Quercetin.
Journal: Biomolecules
Published: July 28, 2021
Vorinostat combined with brigatinib overcomes acquired resistance in EGFR-C797S-mutated lung cancer.
Vorinostat combined with brigatinib overcomes acquired resistance in EGFR-C797S-mutated lung cancer.
Journal: Cancer letters
Published: December 03, 2020
Last Updated: 09/26/2026